Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial
Locker, G.Y.; Khandekar, J.; Krauss, S.; Reisel, H.; Hoeltgen, T.; Wolter, J.; Haid, M.; Hoffman, R.; Blough, R.; Johnson, C.
Cancer Treatment Reports 71(6): 649-650
1987
ISSN/ISBN: 0361-5960 PMID: 3555791 Document Number: 297087
Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). There were five partial responses. Median survival of all patients on study was 36 weeks from entry (48 weeks for those without prior therapy and 34 weeks for those with previous chemotherapy). Toxicity was generally mild and consisted predominantly of stomatitis. In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer.